Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review

dc.contributor.authorContopoulos-Ioannidis, D. G.en
dc.contributor.authorKarvouni, A.en
dc.contributor.authorKouri, I.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T18:54:09Z
dc.date.available2015-11-24T18:54:09Z
dc.identifier.issn1756-1833-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18649
dc.rightsDefault Licence-
dc.subject*Health Surveysen
dc.subjectHumansen
dc.subjectOutcome Assessment (Health Care)en
dc.subjectQuestionnairesen
dc.subject*Randomized Controlled Trials as Topicen
dc.subjectTreatment Outcomeen
dc.titleReporting and interpretation of SF-36 outcomes in randomised trials: systematic reviewen
heal.abstractOBJECTIVE: To determine how often health surveys and quality of life evaluations reach different conclusions from those of primary efficacy outcomes and whether discordant results make a difference in the interpretation of trial findings. DESIGN: Systematic review. DATA SOURCES: PubMed, contact with authors for missing information, and author survey for unpublished SF-36 data. STUDY SELECTION: Randomised trials with SF-36 outcomes (the most extensively validated and used health survey instrument for appraising quality of life) that were published in 2005 in 22 journals with a high impact factor. DATA EXTRACTION: Analyses on the two composite and eight subdomain SF-36 scores that corresponded to the time and mode of analysis of the primary efficacy outcome. RESULTS: Of 1057 screened trials, 52 were identified as randomised trials with SF-36 results (66 separate comparisons). Only eight trials reported all 10 SF-36 scores in the published articles. For 21 of the 66 comparisons, SF-36 results were discordant for statistical significance compared with the results for primary efficacy outcomes. Of 17 statistically significant SF-36 scores where primary outcomes were not also statistically significant in the same direction, the magnitude of effect was small in six, moderate in six, large in three, and not reported in two. Authors modified the interpretation of study findings based on SF-36 results in only two of the 21 discordant cases. Among 100 additional randomly selected trials not reporting any SF-36 information, at least five had collected SF-36 data but only one had analysed it. CONCLUSIONS: SF-36 measurements sometimes produce different results from those of the primary efficacy outcomes but rarely modify the overall interpretation of randomised trials. Quality of life and health related survey information should be utilised more systematically in randomised trials.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1136/bmj.a3006-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19139138-
heal.identifier.secondaryhttp://www.bmj.com/highwire/filestream/339747/field_highwire_article_pdf/0-
heal.journalNameBMJen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
Contopoulos-Ioannidis-2009-Reporting and interp.pdf
Μέγεθος:
127.33 KB
Μορφότυπο:
Adobe Portable Document Format

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: